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Several reports describe regulatory interactions between NK cells and CTLs. We addressed the issue of
NK participation in the early anti-tumor defense by inoculating a-ASGM-1 treated mice with BW-Sp3
T lymphoma. Rejection of BW-Sp3 depends on strong CTL responses. Our results demonstrated that
(i) NK cells are a prerequisite for efﬁcient CTL generation and (ii) the absence of NK cells favors the
outgrowth of alternatively activated macrophages that can suppress CTL restimulation. In vitro studies
demonstrate that in splenic cultures from NK-deﬁcient, tumor-bearing mice, the presence of
alternatively activated macrophages correlates with a lack of Type 1 cytokines, while the production of
Type 2 cytokines is promoted. Provision of the Type 1 cytokine, IFN-g can boost overall CTL activity
but does not revert the dominance of arginase producing adherent cells in the NK-deﬁcient CTL
cultures. The role of NK effector functions in the efﬁcient switch of the immune system towards Type 1
activation was evaluated in cytotoxicity assays. The results indicate that the accessory function of NK
can depend at least partially on their ability to preferentially engage arginase-producing cells,
suggesting that NK/macrophage lytic interactions might be involved in the switch from Type 2 to Type
1-dependent immune responses.
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INTRODUCTION
The contribution of NK cells in the regulation of CTL
activity has been documented in a number of experimental
models, including xenospeciﬁc CTL generation (Smyth
et al., 1998; Smyth and Kelly, 1999), induction of inﬂuenza
virus-speciﬁcCTLs(KosandEngleman,1996)andpriming
oftumor-speciﬁcCTLs(Kurosawaetal.,19 95 ;T er aoetal.,
1996). Overall, in these studies the mechanisms underlying
NK-mediated regulation of CTL activity were not exactly
deﬁned and remain controversial. Indeed, Smyth et al.,
demonstrated that, though CD4
þ T cells are critical for a
mouse anti-human xenospeciﬁc CD8
þ CTL response,
NK1.1
þ cells play an IFN-g-dependent accessory role in
generatingamaximalCTLresponseatthelevelofthelymph
nodes (Smyth et al., 1998; Smyth and Kelly, 1999). On the
other hand, Kos and Engleman provided evidence that NK
cells, but not NK-derived soluble factors, are strictly
required for the generation of inﬂuenza virus-speciﬁc CTL
following infection (Kos and Engleman, 1996). Finally, in
the caseofCD4
þ-dependentpriming of B16 tumor-speciﬁc
CTLs, Terao et al. found that depletion of NK cells before
B16-immunization abrogated tumorspeciﬁc CTL activity.
Furthermore, they observed that NK cells had a promoting
effect on priming of CD4
þ cells, but inhibited the priming
ofCD8
þTcells(Teraoetal.,1996).Kurosawaetal.reﬁned
the latter study and observed that part of the anti-tumor
CTL activity in NK-depleted mice was restored by i.p.
injectionsofIL-2andtoa lowerextentofIFN-g(Kurosawa
et al., 1995).
Besides an immunoregulatory role of NK cells through
cytokine production, these cells might also perform
accessory functions through cell–cell contact-dependent
interaction with antigen presenting cells (APC). Both
positive (activating) (Warschkau and Kiderlen, 1999) and
negative (lytic) (Gilbertson et al., 1986; Djeu and
Blanchard, 1988a,b; Chambers et al., 1996; Geldhof
et al., 1998a; Carbone et al., 1999; Parajuli et al., 1999;
Wilson et al., 1999a,b; Spaggiari et al., 2001) regulatory
interactions have been substantiated. In the
latter condition, several APC surface molecules
were found to be possibly involved in the lytic interaction,
either activating such as B7-1/B7-2 (Chambers et al.,
1996; Geldhof et al., 1998a; Wilson et al., 1999a,b),
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1999), HLA (Spaggiari et al., 2001), or inhibitory such as
CD1 (Carbone et al., 2000) and MHC class I molecules
(Ferlazzo et al., 2001). As such, one might assume that the
functional result of the interaction is determined by the
sum of the opposing signals. Moreover, the outcome of
NK/APC interaction seems to depend on the cytokine
milieu (Ferlazzo et al., 2001; Spaggiari et al., 2001). The
implications of these NK/APC interactions for the
adaptive immune response however remain speculative.
According to recentstudies, differentsubsets of APC can
develop, depending on the resident type 1/type 2 cytokine
balance,namelyclassicallyactivatedAPC(DC1/M1ortype
1-associated) versus alternatively activated APC (DC2/M2
ortype2-associated)andbothareantagonisticallyregulated.
DC1/M1 are the ﬁnal targets and effectors of pro-
inﬂammatory processes (Goerdt et al.,1 9 9 9 ;P u l e n d r a n
et al., 2001), while DC2/M2 appear to participate in anti-
inﬂammatory processes, tolerance induction and wound
healingandexpressadistinctsetofmoleculesandreceptors
used in innate immunity (Stein et al., 1992; Goerdt and
Orfanos, 1999; MacDonald et al., 2001). Both subtypes of
APC can however exert inducing and/or downregulatory
effects on adaptive immune responses.
In this study, we have analyzed the possible involve-
ment of NK cells (via either cytokine production and/or
cytolytic activity) in determining the cellular composition
of APCs and evaluated the resulting effects on anti-tumor
CTL responses. To this end the BW-Sp3 lymphoma model
was adopted since rejection of BW-Sp3 depends on
eliciting strong CTL responses (Van den Driessche et al.,
1994; Raes et al., 1998) and consequently, this model is
appropriate to examine the involvement of NK cells in
early CD8
þ-dependent immune reactions. To address the
importance of NK cells for the early anti-tumor defense,
a-ASGM-1-treated mice were challenged with BW-Sp3
cells. Use of a-ASGM-1 to deplete NK cells was
considered a well-founded option, considering our and
other available information (Beck et al., 1982; Stitz et al.,
1986; Stout et al., 1987). Our results indicate that NK cells
are a prerequisite for efﬁcient CTL generation and that
absence of NK cells favors the outgrowth of a macrophage
population that can be characterized by the dominant
presence of CD11b
þ/GR-1
þ and alternatively activated
adherent cells. Subsequently, we show that these M2 cells,
associated with NK depletion, suppress the restimulation
of CTLs. Finally, preferential engagement of M2 by
activated NK (LAK) cells reveal that cytolytic interactions
might be involved in the regulatory function of NK cells to
drive M1-dependent CTL responses.
RESULTS AND DISCUSSION
Tumor Progression is Favored by NK Cell-depletion
Previously, we have demonstrated that upon subcuta-
neous inoculation, BW-Sp3 T lymphoma cells form
primary tumors that will either progress or regress
(Fig. 1; Raes et al., 1995). The immune effectors
involved in this process reside primarily in the CD8
þ T
cell population. Successful tumor rejection seems to
depend on the generation of an efﬁcient CTL response
within 12 days after tumor challenge, a process that in
our tumor model is mainly CD4
þ helper T cell
independent (Van den Driessche et al., 1994; Raes
et al., 1995, 1998). Indeed, depletion of CD8
þ T cells
results in tumor progression in 100% of the recipients
(Fig. 1). Furthermore, we have shown that all mice that
have rejected the primary tumor challenge, will remain
tumor-free upon rechallenge of BW-Sp3 cancer cells in
the opposite ﬂank (Fig. 1). These results indicate that
subcutaneous inoculation of BW-Sp3 cells can result
in the generation of an adaptive immune memory to
BW-Sp3-dependent antigens and indicate that the
BW-Sp3 tumor cell line is immunogenic. However,
notwithstanding the above-established CTL-dependence
of tumor rejection, also NK cells seem to have a decisive
role in overcoming BW-Sp3 tumors. Indeed, inoculation
of BW-Sp3 in NK-deﬁcient mice will also prevent
efﬁcient clearance of the tumor cells as indicated by
increased tumor growth rate, early death of most of the
recipients (50% of the mice die within 19 days, Fig. 1A)
and a signiﬁcant increase in progressing tumors
(from 66% in immunocompetent mice to 100% in NK-
depleted counterparts, Fig. 1B). Before we pursued the
importance of NK cells in early local anti-tumor immune
responses, we veriﬁed that the antibody we used for
depletion of NK cells in our AKR model, namely anti-
ASGM-1, was uniquely targeting NK cells and did not
eliminate BW-Sp3-speciﬁc CTL. Indeed, some reports
suggest that a-ASGM-1 treatment might also reduce the
pool of Ag-speciﬁc CTL, especially memory CTL raised
during viral infections (Parker et al., 1988; Slifka et al.,
2000). As expected, both the DX5
þ and NKG2
þ NK
populations, which are almost exclusively ASGM-1
þ, are
severely reduced by a-ASGM-1 treatment (results not
shown). However, a-ASGM-1-depletion did not signiﬁ-
cantly inﬂuence the number of antigen-speciﬁc
ASGM-1
þ/CD8
þ T cells, as indicated by FACS (results
not shown) and by BW-Sp3-directed CTL assays. Indeed,
a-ASGM-1-treatment of mice that had rejected a
BW-Sp3 tumor challenge, did not inﬂuence the efﬁciency
of CTL activity when spleens were tested 2 weeks after
antibody treatment (Fig. 2). At this time point NK cells
could have repopulated, but not BW-Sp3-speciﬁc
memory CTL, since mice were absolutely tumor-free.
This indicates that a-ASGM-1 depletion primordially
affects NK cells, but not Ag-speciﬁc T cells. Thus, NK
cells may be implicated in local antitumor responses
against BW-Sp3.
Depletion of NK Results in Enrichment of
CD11b
1/GR-1
1 Cells in the Spleen
Studies from others (Apolloni et al., 2000; Bronte et al.,
2000, 2001; Mazzoni et al., 2002) and our laboratory
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progression with the emergence of a suppressive myeloid
population at the level of the spleen. Bronte et al.,
identiﬁed tumor-produced GM-CSF as the factor respon-
sible for the recruitment of these GR-1
þ/CD11b
þ
immature myeloid progenitors to the spleen (Bronte
et al., 1999). Since BW cells do not produce GM-CSF
(results not shown) this cannot explain their presence in
our late-stage progressors. We have demonstrated in our
earlier studies that NK cells can negatively inﬂuence the
presence of APC (Geldhof et al., 1998a), while other
studies have provided additional evidence for pleiotropic
NK/APC interactions (Gilbertson et al., 1986; Djeu and
Blanchard, 1988a,b; Chambers et al., 1996; Carbone et al.,
1999; Parajuli et al., 1999; Warschkau and Kiderlen,
1999; Wilson et al., 1999a,b; Spaggiari et al., 2001).
Based on our observation that the absence of NK cells
promotes tumor progression early during tumor
growth, we wanted to test the effect of NK depletion
on the distribution of myeloid cells in the tumor-
challenged spleen.
To this end, we examined the distribution of myeloid
surface markers in fresh spleens of immunocompetent
and NK-depleted mice, 7 days after BW-Sp3 tumor
inoculation. Based on the expression of CD11b and GR-1
(a mAb recognizing Ly-6G and Ly-6C) and the FSC/SSC
proﬁles, we subdivided the spleen cells into ﬁve
populations (Fig. 3i, iii). Globally, we obtained a
moderate, but sustained increase in GR-1
þ/CD11b
þ
double positive cells, from 4.2% in immunocompetent-
to 5.9% in NK-depleted hosts (Fig. 3). In late-stage pro-
gressors this increase is more substantial and can be
10-fold higher (Bronte and unpublished results). Notably,
besides moderate increase in number, we could also detect
shifts in surface phenotype. GR-1
high/CD11b
high/SSC
high
cells, comprising mainly neutrophils (Fig. 3i, iii;
population A) express only marginal levels of F4/80 and
CD11c. However, upon depletion of NK cells a new
population appears that expresses high levels of F4/80 and
thus acquires a macrophage phenotype (Fig. 3i). GR-1
þ/
CD11b
þ/SSC
low macrophages (population BE) are
homogenous in both recipients for F4/80 (high) and
CD11c (marginal) expression, though their number also
tends to increase in NK-depleted tumor-bearing hosts.
A second subpopulation of group B (population BD) has
a higher SSC proﬁle, though is comparable in F4/80
and CD11b expression levels to population BE. GR-1
low/
CD11b
þ splenocytes, a mixed population containing DC
FIGURE 1 NK cells positively inﬂuence the efﬁcient rejection of BW-Sp3 T cell lymphoma upon subcutaneous injection. Tumor cells (2.10
6) were
injected subcutaneously in the right ﬂank of immunocompetent or anti-ASGM-1-treated AKR mice. (A) tumor diameter was measured in function of
time; results are represented as the mean tumor diameter (^ s.e.m.) of (i) immunocompetent mice (B), (ii) NK-depleted mice (V) or (iii) CD8-depleted
mice (X) and (B) Percentage of mice with progressing tumors was plotted for naı ¨ve mice, NK-depleted mice, CD8-depleted mice and mice that have
rejected the tumor load, after de novo subcutaneous tumor injection in the opposite ﬂank. *Indicates the time point where 50% of the a-ASGM-1
depleted hosts prematurely succumbed to the tumor load.
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CD11c
high (DC) cells upon depletion of NK cells,
indicating that the proportion of a homogenous GR-1
low/
CD11b
high/F4/80
high/CD11c
þ population increased.
Altogether, in NK-depleted tumor-bearing mice, the
splenic macrophage population increases in number as
well as in F4/80 and CD11b expression level (Fig. 3ii, iv).
Together with the results obtained in late tumor
progressors, this may suggest that NK/myeloid innate
interactions might be involved in shaping the adaptive
BW-Sp3-directed immune response, deciding between
tumor-regression or -progression.
CTL Activity is Impaired in NK-depleted Mice and can
be Partially Reconstituted by Removal of the Adherent
Splenic Fraction
Since BW-Sp3 tumor rejection relies on both CD8
þ
cytolytic T cells (Van den Driessche et al., 1994; Raes
et al., 1995, 1998) and NK cells (see section “Introduc-
tion”), the role of NK cells in early antigen-speciﬁc CTL
activity in tumor-bearing mice was investigated. Spleno-
cytes of 7-days tumor-bearing immunocompetent and
NK-depleted mice were restimulated with Sp3(B7-1)
in vitro for 5 days and subsequently tested for their CTL
activity. In addition, we also evaluated the functional
importance of splenic myeloid cells for the efﬁciency of
the CTL response (see section “Results and Discussion”)
by performing CTL restimulation in the absence or
presence of this cell population. Already 7days post tumor
inoculation, immunocompetent mice generated signiﬁcant
levels of speciﬁc effector CTL’s (15% lysis for
E=T ¼ 100=1), while on the contrary, NK cell depletion
prevented the generation of CTL effector function (4.5%
lysis for E=T ¼ 100=1), barely rising above the lytic
activity of restimulated naı ¨ve splenocytes (3% lysis)
(Fig. 4). The inferior CTL activity of in vitro restimulated
splenic cultures, derived from a-ASGM-1-treated mice,
could be correlated with a lower percentage (12 vs. 8.5%
CD8
þ, Fig. 5A) and a lower level of activation
(5% CD8
þCD69
þ vs. 2.5% CD8
þCD69
þ) of CD8
þ
T cells (Fig. 5A). The absence of NK cells does not reduce
the number of CD4
þ splenocytes nor their activation
status in the restimulated CTL cultures (Fig. 5A). Thus,
NK cells play an accessoryrole in the generation of tumor-
speciﬁc CTL.
Removing the splenic myeloid cells after 2 days of
restimulation, and further culturing the non-adherent
splenocytes for another 3 days, we saw an increase in the
lytic activity of splenocytes from as well immunocompe-
tent (from 15% in total to 31% in non-adherent
splenocytes for E=T ¼ 100=1) as NK-depleted
(from 4.5% in total to 19.3% in non-adherent splenocytes
for E=T ¼ 100=1) 7 days BW-Sp3 tumor-bearing mice
(Fig. 4). These results suggest that in both conditions,
adherent myeloid cells can suppress the efﬁcient
ampliﬁcation of CTL effectors, though the effect
predominates in the NK-depleted condition, where CTL
activity quadruplicates upon removal of the adherent
population, as compared to the immunocompetent
condition where target lysis only doubles (Fig. 4).
Presuming that there is a correlation between suppression
and presence of CD11b
þGR-1
þ cells (Bronte et al., 1999,
2000, 2001; Apolloni et al., 2000; Mazzoni et al., 2002),
we can corroborate the abovementioned ﬁndings by our
FACS data. Indeed, the adherent fractions of both CTL
cultures express signiﬁcant levels of the CD11b
þGR-1
þ
double positive population, increasing from 16% in the
immunocompetent to 22% in the NK-depleted CTL
condition (Fig. 5a). Also note that there is a strong
induction in the number of CD11b
þGR-1
2 cells in the
NK-deﬁcient CTL culture, conﬁrming the ex vivo FACS
results (Fig. 3iii).
Thesedatafurtherstrengthenthenotionthata-ASGM-1
treatment did not deplete the activated T cell pool, but
rather indicate that NK-depletion alters the functional
phenotype of the myeloid splenic fraction to a more
suppressive one. However, note that removal of the
adherentfractiondidnotbringthelyticpotentialoftheNK-
depleted CTL culture to the same level as the
immunocompetent CTLs, suggesting that some of
the effects of in vivo NK depletion cannot be reverted by
removing suppressive macrophages during in vitro
restimulation. One possibility may reside in the effect
of NK depletion on the dendritic cell pool. Indeed, the
ex vivo results represented in Fig. 3 suggest that
the CD11c
high expressing DC pool is underrepresented in
NK-depleted cultures, which could result in inefﬁcient
FIGURE 2 a-ASGM-1 treatment predominantly targets NK cells, but
not activated T cells. Splenocytes from naı ¨ve mice (A), mice that rejected
the local tumor load (S), or mice that had rejected the BW-Sp3 tumor
load and received one a-ASGM-1 treatment 2 weeks prior (D), were
collected and were restimulated in vitro with irradiated BW-Sp3(B7-1)
cancer cells. After 5 days, viable lymphocytes were collected. Cytolytic
activity of effector CTL was measured in a 4h
111In-release assay against
BW-Sp3(B7-1) target cells at different Effector/Target ratios. Results are
represented with SEM.
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tumor challenge. Accordingly, recent results from Piccioli
et al., reported on stimulatory effects of NK on autologous
DCmaturationandDCcytokineproduction(Picciolietal.,
2002).
Since NK cells can be active producers of cytokines,
supporting as well type 1 as type 2 immune responses
(Cooperetal.,2001; Lozaand Perussia,2001;Deniz etal.,
2002), we also checked the cytokine proﬁles in the spleen
72h after initiation of in vitro restimulation. As expected,
effective induction of CTL activity was paralleled by high
levels of IFN-g secretion during in vitro culture (Fig. 5B).
Depletion of NK cells not only abrogated IFN-g
production, but also signiﬁcantly induced the production
of type 2-associated cytokines IL-4, IL-13 and IL-10
(Fig. 5B). This implies that in our AKR derived BW-Sp3
tumor model, NK cells are prerequisite for the generation
of type 1 immune responses and that in their absence, the
immune system will have a tendency to further evolve in
the direction of type 2-dominated responses. To analyze
the implication of the shift in the type1/type2 cytokine
balance on the activation status of the myeloid population,
we also measured NO production in the cultures and
arginase activity in lysates of the adherent fractions
(Fig. 5B). Interestingly, macrophages that were activated
in immunocompetent conditions tend to produce NO
(classical activation), while macrophages activated in the
absence of NK primordially produce L-ornithine and urea
via the arginase pathway (alternative activation) (Munder
et al., 1998). Note also that the production of monocyte
chemoattractant protein-1 (MCP-1), possibly implicated
in the recruitment of myeloid cells to the spleen, is
FIGURE 3 CD11b
þ/GR-1
þ cells are enriched and underwent a phenotypical shift in NK-depleted tumor bearing mice. Splenocytes from
immunocompetent and a-ASGM-1-treated, day 7, tumor-bearing mice were collected and after Fc receptor blocking immediately surface-stained with
myeloid-speciﬁc antibodies. Splenocytes were double-stained with a-GR-1-PE and a-CD11b-FITC and subsequently subdivided in CD11b
2,
CD11b
highGR-1
high (population A), CD11b
þGR-1
þ (population B) and CD11b
þGR-1
low (population C) populations for immunocompetent (i) and NK-
depleted (iii) conditions. SSC/FSC proﬁles and histograms representing the distribution of F4/80 and CD11c expression are represented for each of the
CD11b
þ subpopulations. Population B was further subdivided in two cell groups based on their SSC/FSC proﬁles (groups D and E). Macrophage
maturation stage in the spleen was further determined by plotting the expression of F4/80 in function of CD11b for as well immunocompetent (ii) as NK
depleted (iv) recipients.
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et al., 2001). Altogether our results indicate that NK
depletion can selectively fuel the development of type 2-
immune responses.
Our results complement some of the observations made
with immunosuppressive macrophages that have been
identiﬁed in the lymphoid organs of immunosuppressed,
tumor-bearing mice and comprise a population of
immature Gr1
þ/CD11b
þ myeloid precursors (Bronte
et al., 1999; Kusmartsev et al., 2000; Gabrilovich et al.,
2001). Exposure of these Gr1
þ/CD11b
þ cells to IL-4 (type
2 cytokine) greatly increased the T lymphocyte suppres-
sive activity of this population, while type 1 cytokines
induced their maturation into competent mature DC1
(Apolloni et al., 2000; Bronte et al., 2000). Besides those
functional similarities, the myeloid suppressor cells show
some important differences from alternatively activated
macrophages described by us and others. The authors
themselves acknowledge the dissimilarities between their
Gr-1
þ/CD11b
þ adherent population and M2, stressing the
immature phenotype of their suppressor myeloid cells
(Bronte et al., 2000). Moreover, we can add some
additional deviating features: First, none of the studies
report the production of arginase in their suppressor cells.
Finally, the alternatively activated macrophages in our
model express Fas-L, FcRg and B7 (unpublished results)
in contrast to the myeloid precursor (Bronte et al., 2000).
Further characterization of the phenotype of the
suppressor cells and mechanism of suppression is
currently under investigation.
IFN-g can Boost CTL Activity in NK-competent and
Depleted Conditions
IFN-g is one of the main factors produced by NK cells,
early after immune challenge with cancer cells or
infectious agents. Moreover NK-produced IFN-g has
been described to be critical for the promotion of adaptive
T cell responses (Seaman et al., 1987; Gray et al., 1994;
Salazar-Mather et al., 1996, 1998; Smyth and Kelly,
1999). Since in our experimental set-up, NK depletion
parallels the lack of IFN-g production, we decided to
determine the relative importance of IFN-g for the
induction of antitumor CTLs. To this end, we provided
recombinant IFN-g to immunocompetent or NK-depleted
tumorbearing mice on one hand and blocking a-IFN-g
antibodies to immunocompetent BW-Sp3 inoculated mice
on the other hand. Provision of anti-IFN-g during tumor
growth reduced the CTL-inducing capacity of tumor-
challenged mice. Indeed, the lytic activity of CTLs
derived from anti-IFN-g-treated mice (6.6% speciﬁc
release at effector/target ratio 100/1) barely exceeds the
lytic activity of NK-deﬁcient CTL cultures (4.5% speciﬁc
release) (Fig. 6A). Providing excess IFN-g to a-ASGM-1
treated mice, brings the efﬁciency of CTL induction
almost to the level of immunocompetent mice (12%
speciﬁc release in IFN-g treated NK deﬁcient mice, as
compared to 15% in immunocompetent hosts, Fig. 5A).
However, providing the same quantities of IFN-g to
immunocompetent recipients, results in an even more
drastic increase in CTL activity. Percentage speciﬁc
release goes from 15%, using CTLs from normal 7 day
BW-Sp3 tumorbearers as effectors, to 47% speciﬁc
release when IFN-g is provided during tumor growth
(Fig. 6A). This indicates that IFN-g is very efﬁcient at
boosting early CTL responses, especially in immuno-
competent, but only to a lesser extend in immunodysfunc-
tional environments. We conﬁrmed this observation by
determining the inﬂuence of IFN-g-treatment on the
activation status of splenic macrophages in the CTL
cultures. Though IFN-g is typically used to steer
macrophages to classical, type 1-dependent activation
(Munder et al., 1998), in our experimental set-up, IFN-g
will only have marginal effects on macrophage phenotype.
Indeed, though arginase activity is reduced by IFN-g
(from 80 to 0mU) and marginally induced by a-IFN-g
treatment (from 80 to 130mU) in immunocompetent
mice, provision of IFN-g to NK-depleted mice will not
reduce the inherent type 2 prevalence of the macrophage
population. Thus NK-produced IFN-g cannot solely
explain the CTL-deﬁciency observed in NK-depleted
mice, indicating that other NK factors and/or functions are
involved in biasing type 2 responses in the spleen. A direct
interaction between BW-Sp3 cancer cells and innate cells
(NK cells, activated macrophages) via Rae-1/NKG2D
FIGURE 4 Functional role of NK cells in generation of anti-BW-Sp3
CTLs. Splenocytes from naı ¨ve, immunocompetent or a-ASGM-1-
treated, 7 days, BW-Sp3 tumor bearing AKR mice were restimulated
in vitro with irradiated cancer cells. After 5 days, viable lymphocytes
were collected, (open symbols). Alternatively, 2 days after initiation of
restimulation, adherent splenocytes were removed and restimulation
of the non-adherent fraction was continued for another 3 days to obtain
so-called non-adherent effectors (NA-CTL) (ﬁlled symbols). Cytolytic
activity of effector CTL was measured in a 4h
111In-release assay against
BW-Sp3(B7-1) target cells.
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cellular immune responses leading to type 1 associated
adaptive tumor immunity (including generation of CTLs)
(Cerwenka et al., 2000, 2001; Diefenbach et al., 2001).
Consequently, in this scenario the link between CTL
and NK activity could rely primarily on the production of
NK-derived type 1 cytokines as was suggested in other
studies (Kurosawa et al., 1995; Smyth and Kelly, 1999).
However, the evidence that was so far provided for a
direct role of NK-derived IFN-g and/or other cytokines on
CTL generation is debatable (see “Introduction”) and is
further refuted by our results.
Conditioning of Splenic Adherent Cells in a Dominant
Type 2 Environment Induces their NK Susceptibility
Considering that APC can become sensitivetargets for NK
lysis if they express the proper balance of NK
activatory/inhibitory signals (Gilbertson et al., 1986;
Djeu and Blanchard, 1988a,b; Chambers et al., 1996;
Geldhof et al., 1998a; Carbone et al., 1999; Parajuli et al.,
1999; Warschkau and Kiderlen, 1999; Wilson et al.,
1999a,b; Spaggiari et al., 2001) and taking into account
thatNK-producedIFN-gisnotsufﬁcienttoreverttheType
2 propensity of macrophages (Fig. 6B), we considered the
possibility that the lytic function of NK cells may
contribute to its adverse effect on Type 2 macrophages.
Therefore, we collected the adherent fractions of
immunocompetent and NK-depleted CTL cultures, 3
days after initiation of the in vitro cultures and included
them as targets in a LAK assay. Using IL-12 activated NK
cells as effectors we could clearly detect superior lysis of
Type 2 macrophages as compared to Type 1 conditioned
macrophages (Fig. 7). Notably, adherent cells isolated
from naı ¨ve splenic cultures showed intermediate sensi-
tivity, suggesting that Type 1-dependent activation will
protect macrophages from NK-mediated lysis, while
Type 2 activation will induce their NK sensitivity (Fig.
7). Thus, alternatively activated macrophages from NK-
deﬁcient conditions were signiﬁcantly better lysed than
classically activated macrophages from immunocompe-
tent cultures. This is consistent with early publications
suggesting that invitro IFN-g (Type 1 cytokine) treatment
of tumor cells (Gronberg et al., 1989) or monocytes (Djeu
and Blanchard, 1988a,b) can confer protection to LAK
lysis. Hence NK cells can be involved in preferential
FIGURE 5 Depletion of NK cells alters the cellular composition and the Th1/Th2 cytokine balance in splenic derived CTL cultures. Splenocytes from
naı ¨ve, immunocompetent or a-ASGM-1-treated, 7 days, BW-Sp3 tumor bearing AKR micewere restimulated invitro with irradiated cancer cells. After
3 days, cell-free supernatants were collected, adherent cells were separated from non-adherent cells and subjected to analysis. (A) Percentages of
CD8
þ/CD69
þ, CD4
þ/CD69
þ T cells (non-adherent) and GR-1
þ/CD11b
þ myeloid cells (adherent) in 3 day restimulated CTL cultures were analyzed
by FACS and represented in Dot Plots. (B) Supernatant from CTLcultures wastested forNO (mM/10
6 cells), IFN-g (U/ml), IL-4(pg/ml),IL-10 (pg/ml),
IL-13 (pg/ml) and MCP-1 (pg/ml). Arginase activity was determined in the adherent fraction of restimulated spleens. The concentrations are represented
as quantity produced per 10
6 adherent cells.
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phages in vivo.
Inconclusion,thehereinpresentedresultsunequivocally
link NK activity and CTL-mediated anti-tumor responses
and furthermore provide evidence for novel regulatory
mechanisms possibly implicated in the NK/CTL inter-
action. Indeed, our analysis of the involvement of NK cells
in the BW-Sp3 tumor model revealed the following main
ﬁndings: (i) Progression of BW-Sp3 tumors leads to
impaired anti-cancer cell CTL and NK cell activities and
depletion of NK cells during the early phase of BW-Sp3
tumor development impairs the development of CTL
responses and increases tumor progression; (ii) NK cell
depletion during early BW-Sp3 tumor formation changes
the macrophage number and phenotype in the spleen,
leading to increased levels of CD11b
þ/GR-1
þ double
positive cells; (iii) NK-depletion alters the tumor-elicited
splenic cytokine production in favor of a Type 2 cytokine
microenvironment and promotes the development of
alternatively activated splenic macrophages; (iv) M2
enriched splenic adherent cells suppress potently CTL
activity; (v) provision of excess IFN-g can boost
immunocompetent and NK-depleted CTL activity, but
does not revert underlying NK-mediated macrophage
defects; (vi) alternatively activated splenic macrophages
cells are more susceptible to NK-mediated lysis as
compared to classically activated macrophages.
Collectively, we provide evidence for the involvement
of NK/macrophage lytic interactions in the switch from
Th2 to Th1-dependent immune responses and corroborate
the crucial role of NK cells in the development and
maintenance of anti-tumor CTLs. Our study further points
to a new regulatory mechanism possibly implicated in the
NK/CTL interaction, namely NK-mediated control
of suppressive M2-like populations, that may rely on
both NK-mediated regulatory (i.e., initiation of type 1
oriented signaling) as well as NK-mediated cytolytic
(i.e., elimination of M2 cells) activities. Hence a
regulatory pathway linking NK cells, M2 cells and CTLs
can be operative in cancer.
FIGURE 6 IFN-g can boost overall CTL responses but does not block the development of arginase-producing alternatively activated macrophages.
Mice were treated with a-IFN-g, a-ASGM-1 and/or recombinant IFN-g and subsequently challenged with BW-Sp3 subcutaneously. Seven days after
tumor inoculation, spleens were harvested and restimulated in the presence of irradiated BW-Sp3(B7-1) for 5 days. (A) Viable non-adherent splenocytes
were collected and included in an in vitro cytotoxicity assay. The results represent cytolytic activity toward BW-Sp3(B7-1) at an E/T ratio of 100/1.
(B) The adherent fraction of the CTL cultures were collected by scraping and arginase activity was determined in the lysate of 10
6 viable cells.
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Mice
Speciﬁc pathogen-free female AKR (Thy1.1, H-2
k) mice
were obtained from Harlan CPB (Zeist, The Netherlands).
Tumor Cell Lines
The BW-Sp3 cell line was derived from the original
spontaneous BW5147 T cell lymphoma (referred to as
BW-O) (AKR origin, Salk Institute, La Jolla, CA) by
in vitro and in vivo passages, as described previously
(Geldhof et al., 1998b). The generation of BW-Sp3(B7-1)
was described earlier (Raes et al., 1998).
CTL Induction
For the generation of CTL, spleens from tumor-bearing
mice were taken and splenocytes from two spleens were
restimulated in ﬂasks in the presence of 10
7 irradiated
(110Gy) cancer cells. Five days later the cytolytic activity
of the viable lymphocytes, separated on a Ficoll gradient
(Amersham Pharmacia), were tested in a classical
111In release assay (Geldhof et al., 1995). Alternatively,
adherent cells from primary CTL cultures were removed
by transferring the non-adherent fractions to new plates,
2 days after initiation of the CTL restimulation and culture
was continued for another 3 days before they were
included in CTL assays.
In Vivo Experimental Settings
For in vivo NK depletion, AKR mice were injected
intravenously in the tail with 0.2ml of a tenfold dilution in
phosphate buffered saline (PBS) of a-ASGM-1 antibodies
(Wako Chemicals, Osaka, Japan), 24h prior to tumor
inoculation and repeated every 4–5 days during the course
of the experiment. In NK depletion experiments, speciﬁc
depletion was greater than 95%. Mice in groups of six
were injected subcutaneously in the right ﬂank with 2.10
6
cancer cells in 0.2ml PBS. For every treatment, mortality
of the hosts, fraction of regressors/progressors and tumor
growth (by measuring the local tumor diameter) were
followed up twice a week. For in vivo treatment with
recombinant IFN-g, mice were injected intraperitoneally
with 100.000 units IFN-g 24h prior to and 3 days after
tumor injection. Treatment with a-IFN-g antibodies was
done once, injecting 0.5mg intraperitoneally 24h before
tumor treatment.
Generation of A-LAK Cells
Mouse spleen cells were isolated and nylon wool non-
adherent cells were harvested as described in detail
elsewhere (Geldhof et al., 1995, 1998a). The nylon
woolnon-adherentcellswerebroughttoaconcentrationof
2 £ 106=ml in RPMI medium, supplemented with
0.3mg/ml L-glutamine, 100U/ml penicillin, 0.1mg/ml
streptomycin, 10% FCS, 5 £ 1025 M mercapto-ethanol
( ¼ CM)and1000U/mlIL-2(Eurocetus,Netherlands)and
incubated at 378Ci n5 %C O 2 and 100% humidity during
5days.ForthegenerationofIL-2/IL-12LAK,recombinant
mouse IL-12 (generously provided by Genetics Institute,
Inc., Cambridge, MS, USA), was added to the IL-2 LAK
cultures at100U/ml, 72hafter initiationof the cultures for
another 48h. The adherent cell fraction is harvested with
0.01%EDTAinPBSandusedaseffectorcellpopulationin
111In-release cytotoxicity assays.
111In-release Cytotoxicity Assay
The target cells were labeled with
111In by incubating 10
6
cells in 100ml (RPMI þ 5% FCS) with 0.1mCi
111InCl
(Amersham, Belgium) during 10min (Geldhof et al.,
1995). After extensive washing, 10
4 target cells were
incubated with 2-fold dilutions of effector cells in a total
volume of 200ml CM in 96-well round bottom plates.
All experiments were performed in triplicates and twice
repeated. After 4h at 378C, the plates are centrifuged
3min at 600r.p.m., 100ml of supernatants is collected and
radiation is counted in a g-counter. The percentage of
speciﬁc lysis was calculated as ((experimental release 2
spontaneous release)/(maximal release 2 spontaneous
release)) £ 100, where the spontaneous release was
determined from labeled targets cells incubated without
effector cells and maximal lysis from target cells
incubated 1h before harvesting in 2% SDS.
FIGURE 7 LAK cells differentially lyse M1 vs. M2 cells. The activity
of IL-2/IL-12 activated LAK cells was measured in an in vitro
cytotoxicityassay.Sensitivityofadherentcells,isolatedfromspleencells
cultured during 3 days in vitro, to LAK effector cells was tested. Spleens
were isolated from naı ¨ve (O), 7 day BW-Sp3 tumor bearing (V), and
a-ASGM-1-treated, 7 day BW-Sp3 tumor bearing (†) AKR.
Spontaneous release was # 17% for splenocytes. One representative
experiment of two is shown, indicating the mean percentage speciﬁc
release of targets in triplicate (^s.e.m.). Standard deviations of less than
3% are not shown for sake of clarity.
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Arginase activity was measured in cell lysates with slight
modiﬁcations as previously described (Namangala et al.,
2001). Brieﬂy, cells were lysed with 100ml of 0.1% Triton
X-100.After30minonashaker,100mlof25mMTris-HCl
was added. To100mlofthislysate,35mlof10mM MnCl2
was added, and the enzyme was activated by heating for
10min at 568C. Arginine hydrolysis was conducted by
incubating 40ml lysate with 40ml of 0.5M L-arginine, pH
9.7, at 378C for 60min. The reaction was stopped with
320mlo fH 2SO4/H3PO4/H2O (1/3/7, v/v/v). The urea
concentration was measured at 540nm after addition of
16mlo f9 %a-isonitrosopropiophenone (dissolved in
100%ethanol)followedbyheatingat958Cfor30min.One
unit of enzyme activity is deﬁned as the amount of enzyme
that catalyzes the formation of 1mmol of urea per minute.
NO Measurement
NO was measured as nitrite using the Griess reagent.
Culture supernatant was mixed with 100ml of 1% sulfanil-
amide, 0.1% N-(1-naphthyl)ethylenediamine dihydro-
chloride, and 2.5% H3PO4. Absorbance was measured at
540nm in a microplate reader.
Cytokine Assays
The production of IL-4, IL-10, IL-13, MCP-1, and IFN-g
was quantiﬁed by subjecting culture supernatants to
commercially available (Pharmingen, San Diego, CA,
USA) sandwich ELISA tests according to the manufac-
turers’ protocols.
FACS Staining and Analysis of Adherent and
Non-Adherent Spleen Cells
Cell samples comprising 10
6 cells were incubated with the
appropriate dilutions of antibodies, as suggested by the
distributors, at 48C for periods of 30min. Rat anti-CD11b-
FITC, anti-CD69-FITC, anti-CD25-FITC, anti-GR-1-PE,
anti-CD4-PE, anti-CD8-PE, anti-CD11c-biotin and SA-
APC were purchased from Pharmingen (San Diego, CA,
USA), anti-F4/80-biotin from Serotec. To prevent FcR-
mediated binding of staining antibodies, the Fc-receptors
were blocked with 2.4G2 (ATTC) derived F(ab)2
antibodies,priortotheadditionoftheindicatedantibodies.
As isotype controls for a speciﬁc binding of rat, mouse and
hamster anti-mouse antibodies, control antibodies were
purchased from the distributors and included during FACS
staining.ThestainedcellsweresubjectedtoFACSanalysis
with the Becton-Dickinson FACS Vantage coupled to an
Apple Macintosh FACStation. The results were analyzed
with the CellQuest program.
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